Login to Your Account



Anemia Drug Warning Extended as FDA Panel Prepares to Ponder

By Donna Young


Tuesday, March 11, 2008
Amgen Inc. and Ortho Biotech Products LP preempted an FDA advisory panel review of Aranesp, Epogen and Procrit by strengthening the anemia drugs' black-box warnings with new safety language about the risks of using the products in patients with breast and cervical cancers. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription